Substantia nigra

China Medical University Hospital's New Tech "AI-aided Diagnostic System" Assist to Diagnose Freezing of Gait (Parkinson's Disease) in Just 30 Minutes

Retrieved on: 
Thursday, March 21, 2024

Early stages of PD gait disorders require detailed neurological examinations and tests for accurate diagnosis.

Key Points: 
  • Early stages of PD gait disorders require detailed neurological examinations and tests for accurate diagnosis.
  • China Medical University Hospital (CMUH) AI Center and the Department of Neurology have utilized AI auxiliary tools to analyze the patient's gait videos and walkway pressure data utilizing the AI algorithms, to construct an "AI-aided diagnostic system for freezing of gait."
  • Noticeable symptoms of the early onset include limb tremors, slowness of movement, muscle and joint stiffness, hunched back, scoliosis, etc.
  • This system is particularly beneficial for patients in rural areas, reducing the need for hospital visits:
    Time-saving: instantly assist in the diagnosis within 30 minutes of completion of the freezing of gait examination.

Olatec Therapeutics to Conduct a Phase 2 Clinical Trial in Patients with Early Parkinson’s Disease with its NLRP3 Inhibitor, Dapansutrile

Retrieved on: 
Tuesday, February 20, 2024

Olatec Therapeutics, Inc. (Olatec), a leader in the developing class of selective NLRP3 inhibitors, today announced that Cure Parkinson’s granted an award to initiate a Phase 2 clinical trial investigating the potential of oral dapansutrile to slow or stop the progression of Parkinson’s disease.

Key Points: 
  • Olatec Therapeutics, Inc. (Olatec), a leader in the developing class of selective NLRP3 inhibitors, today announced that Cure Parkinson’s granted an award to initiate a Phase 2 clinical trial investigating the potential of oral dapansutrile to slow or stop the progression of Parkinson’s disease.
  • Parkinson’s is a complex neurodegenerative disease, which as reported by Cure Parkinson’s, is the fastest growing neurological condition in the world.
  • Treatment with dapansutrile has the potential to arrest this cyclical process of cell damage thereby slowing the progression of the disease.
  • The trial will seek to enroll 36 participants with early Parkinson’s disease.

Terran Biosciences Receives FDA Clearance for NM-101, the industry’s first software for the analysis of neuromelanin-sensitive MRI

Retrieved on: 
Wednesday, December 20, 2023

Terran Biosciences, Inc. ("Terran"), a biotech platform company developing therapeutics and technologies for patients with neuropsychiatric illnesses, has received FDA clearance to market NM-101, a cloud-based software platform to analyze neuromelanin-sensitive MRI scans.

Key Points: 
  • Terran Biosciences, Inc. ("Terran"), a biotech platform company developing therapeutics and technologies for patients with neuropsychiatric illnesses, has received FDA clearance to market NM-101, a cloud-based software platform to analyze neuromelanin-sensitive MRI scans.
  • Currently, there is no other FDA-cleared software indicated for the analysis of neuromelanin MRI on the market, making Terran’s technology the world’s first.
  • NM-101 is a cloud-based analysis platform that is able to seamlessly integrate into existing workflows at hospitals and imaging centers.
  • NM-101 contains algorithms that enabled for the first time the fully automated analysis and the cross-scanner harmonization of neuromelanin MRI scans [8-10,12,13].

Parkinson's Disease in 7 Major Markets Report 2023: Epidemiology, Disease Management, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Pipeline Analysis 2019-2029 - ResearchAndMarkets.com

Retrieved on: 
Friday, November 3, 2023

The "Parkinson's Disease by Major Markets - Size, Trends and Drug Forecast including Epidemiology, Disease Management, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Pipeline Analysis to 2029" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Parkinson's Disease by Major Markets - Size, Trends and Drug Forecast including Epidemiology, Disease Management, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Pipeline Analysis to 2029" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report encompasses the 7 Major Markets (US, France, Germany, Italy, Spain, UK, Japan) and includes an Excel-based forecast model for the Parkinson's Disease market, extending through the year 2029.
  • Anticipated growth in the PD market is driven by an increasingly aging population, complemented by the introduction of 14 pipeline products across the 7 Major Markets.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the PD therapeutics market.

Gain Therapeutics Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of its Drug Candidate GT-02287 in GBA1 Parkinson’s Disease Model

Retrieved on: 
Monday, August 28, 2023

BETHESDA, Md., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced preclinical data demonstrating the Company’s lead drug candidate GT-02287 significantly decreased Parkinson’s disease (PD)-associated pathology and improved motor dysfunction in two different preclinical models of Parkinson’s disease. Of note, GT-02287 significantly reduced plasma Neurofilament Light Chain (NfL) levels, an emerging biomarker for neurodegeneration, in a mouse model of GBA1-PD. The findings are being presented in two posters, including one that was accepted as a late breaking abstract, at the International Congress of Parkinson's Disease and Movement Disorders® being held in Copenhagen, Denmark from August 27-31, 2023.

Key Points: 
  • Of note, GT-02287 significantly reduced plasma Neurofilament Light Chain (NfL) levels, an emerging biomarker for neurodegeneration, in a mouse model of GBA1-PD.
  • Researchers used a mouse model of GBA1-PD, created using conduritol beta epoxide (CBE) to induce GCase deficit comparable to GBA1-PD.
  • Data from the poster describes the effect of GT-02287 on rotenone-induced neurotoxic effects in a PD animal model.
  • “Buoyed by these encouraging data, we look forward to initiating the Phase 1 clinical study with GT-02287 and advancing the development of this potentially best-in-class treatment for GBA1 Parkinson’s disease.”

NysnoBio Awarded Michael J. Fox Foundation Grant to Advance Parkin Gene Therapy

Retrieved on: 
Monday, July 17, 2023

SAN FRANCISCO, July 17, 2023 (GLOBE NEWSWIRE) -- NysnoBio, a biopharmaceutical company pioneering the development of Parkin gene replacement therapy for patients with severe diseases, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to assist the advancement of the company’s lead Parkin gene replacement therapy candidate, NB001. The funding will support product manufacturing to enable IND safety studies in preparation for human clinical trials evaluating NB001 in Parkinson’s Disease (PD) patients with bi-allelic loss-of-function mutations in the Parkin gene, or Parkin-PD.

Key Points: 
  • Fox Foundation for Parkinson’s Research (MJFF) to assist the advancement of the company’s lead Parkin gene replacement therapy candidate, NB001.
  • The Parkin gene is a key regulator of dopamine neuronal health through its established role to orchestrate the removal of damaged mitochondria.
  • NB001 Parkin gene replacement therapy aims to restore dopaminergic function and give these patients the prime of their lives back.
  • Over the last 20 years, the NysnoBio team has pioneered the basic biochemistry and therapeutic potential for the Parkin gene.

Why a holiday is good for you – even before you take time off

Retrieved on: 
Wednesday, July 12, 2023

And the truth is that the benefits of a good holiday can be felt even before the trip begins.

Key Points: 
  • And the truth is that the benefits of a good holiday can be felt even before the trip begins.
  • Scientific studies show that merely looking forward to a future reward can be even more rewarding than the reward itself.
  • This is so thanks to a small molecule called dopamine, which we will talk about later.

Rest increases cognitive flexibility

    • This was concluded by a 2016 study in which 46 workers from a Dutch company participated.
    • What the researchers observed is that, after two or three weeks of vacation, workers had greater cognitive flexibility.
    • Most studies concur that, from a biological point of view, one of the main reasons for this increase in cognitive flexibility –and for the benefits of holidays in general– is stress reduction.
    • But we have to make a small distinction here: stress in and of itself does not have to be bad.

Recipe for a holiday that recharges your batteries

    • When we are idle, our brain is able to reverse – at least temporarily – the negative effects of being under stress.
    • And here comes the key: for holidays to be truly effective, we have to ensure that they really free us from the stress of our work.
    • Of course, what one finds rewarding is entirely subjective, and what is pleasant for one person can cause stress for others.

To enjoy or not to enjoy

    • The worst thing is that the changes do not only occur in the substantia nigra or in the ventral tegmental area.
    • It has been found that chronic stress is even capable of changing the number of dopamine receptors in the areas that receive these projections.
    • Therefore, a vacation that frees us from stress will help to rebalance the dopaminergic system.

Preclinical Safety and Efficacy Data for ANPD001 Presented by Dr. Andres Bratt-Leal at 2023 World Parkinson Congress in Barcelona

Retrieved on: 
Thursday, July 6, 2023

SAN DIEGO, July 6, 2023 /PRNewswire/ -- On Wednesday at the 2023 World Parkinson Congress in Barcelona, Aspen Neuroscience co-founder Andres Bratt-Leal, PhD, Senior Vice President Research & Development, presented preclinical safety and efficacy data for the first time for ANPD001, Aspen's iPSC-derived lead candidate for treatment of Parkinson's Disease (PD).

Key Points: 
  • SAN DIEGO, July 6, 2023 /PRNewswire/ -- On Wednesday at the 2023 World Parkinson Congress in Barcelona, Aspen Neuroscience co-founder Andres Bratt-Leal, PhD, Senior Vice President Research & Development, presented preclinical safety and efficacy data for the first time for ANPD001, Aspen's iPSC-derived lead candidate for treatment of Parkinson's Disease (PD).
  • Dr. Bratt-Leal's poster presentation, "Preclinical Safety and Efficacy of Dopamine Neuron Precursor Cells Derived from PD Donor-Induced Pluripotent Stem Cells," featured GLP safety and efficacy data in well-established rodent models.
  • In the studies, dopamine neuron precursor cells (DANPCs) were generated from six different skin biopsies, donated by people diagnosed with Parkinson's Disease.
  • These autologous iPSCs were further differentiated to DANPCs, which were then tested for efficacy in a well-known rodent model of PD.

Neuronascent to Present New Parkinson’s Model Data at AAIC 2023 for the Alzheimer’s Disease Investigational Therapy, NNI-362

Retrieved on: 
Wednesday, June 28, 2023

The main intent of this Parkinson’s model work was to assess the capacity of NNI-362, to regenerate neurons and ameliorate behavioral deficits for age-related neurodegenerative disorders in those regions of the brain where disease is present.

Key Points: 
  • The main intent of this Parkinson’s model work was to assess the capacity of NNI-362, to regenerate neurons and ameliorate behavioral deficits for age-related neurodegenerative disorders in those regions of the brain where disease is present.
  • The Phase 1a trials were successfully completed in a healthy aged population in 2021, for Alzheimer’s disease, and Neuronascent aims to continue toward Phase 2 proof-of-concept trials for more than one age-related, neurodegenerative indication.
  • To determine whether NNI-362 could support disease-specific regeneration of neurons outside of the hippocampus, an AAV-alpha synuclein model of Parkinson’s disease was run at Motac, France, under the guidance of Dr. Erwan Bezard.
  • This work aims to assess whether NNI-362 is disease-agnostic, such that in aging the neurodegeneration can be reversed no matter the triggers of disease neuron degeneration.

Voyager Therapeutics Presents Robust, Multi-Species Results from Preclinical Studies of IV-Delivered, TRACER™-Generated Novel Capsids at the ASGCT 26th Annual Meeting

Retrieved on: 
Thursday, May 18, 2023

These results are being presented at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting, taking place May 16-20, 2023, in Los Angeles.

Key Points: 
  • These results are being presented at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting, taking place May 16-20, 2023, in Los Angeles.
  • “These data demonstrate that our TRACER capsid discovery platform is able to generate brain-penetrant capsids in a highly reproducible manner,” said Todd Carter, Chief Scientific Officer of Voyager Therapeutics.
  • In these studies, VCAP-102 demonstrated de-targeting of the dorsal root ganglia (DRG) and liver.
  • Researchers identified a new capsid called VCAP-103, which demonstrated enhanced brain and spinal cord transduction in marmosets and African green monkeys.